These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31154671)

  • 1. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 3. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
    Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
    Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
    Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
    Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What does meaningful look like? A qualitative study of patient engagement at the Pan-Canadian Oncology Drug Review: perspectives of reviewers and payers.
    Rozmovits L; Mai H; Chambers A; Chan K
    J Health Serv Res Policy; 2018 Apr; 23(2):72-79. PubMed ID: 29624087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cancer drug wastage on economic evaluations.
    Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
    Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
    McDonald H; Charles C; Elit L; Gafni A
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.